Status:
RECRUITING
Antimicrobial Therapy for Difficult-to-treat Pseudomonas Aeruginosa
Lead Sponsor:
Centre Hospitalier Régional d'Orléans
Conditions:
Pseudomonas Infections
Pseudomonas Aeruginosa
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of the ADDICT study is to assess and compare the clinical efficacy of available options for antimicrobial therapy (new beta-lactam/beta-lactamase inhibitor combination, cefideroc...
Detailed Description
Infections due to Pseudomonas aeruginosa isolates with acquired resistances to all first-line antipseudomonal beta-lactams and fluoroquinolones (difficult-to-treat isolates - DTR), pose serious therap...
Eligibility Criteria
No eligibility criteria provided.
Key Trial Info
Start Date :
March 11 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2027
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06738771
Start Date
March 11 2025
End Date
January 1 2027
Last Update
April 17 2025
Active Locations (48)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France
2
CH Argenteuil
Argenteuil, France
3
CH Bayonne
Bayonne, France
4
CHU de BESANCON
Besançon, France